News

MedPage Today on MSN11h
First-Line Keytruda-Trodelvy Boosts PFS in Triple-Negative Breast Cancer
CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...
Targeted Oncology21h
Sacituzumab Govitecan/Pembro Shows Promise in First-Line PD-L1+ mTNBC
Sara M. Tolaney, MD, MPH, shares new data from the ASCENT-04 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer.
Gilead’s Trodelvy with Merck’s Keytruda cuts disease progression/ death in breast cancer
Gilead Sciences (NASDAQ:GILD) announced Saturday that its antibody-drug conjugate Trodelvy, in combination with Merck’s (NYSE ...